Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

<< Previous

Bullboard Posts

Next >>

Post by 99942Apophison Sep 07, 2021 4:56pm

470 Views

Post# 33822113

From Company Website

I would say 12 of 15 is close to a majority out of 15 planned sites

Once the majority of the planned 15 clinical study sites are launched, enrolling and treating patients is the pivotal Phase II NMIBC clinical study (“Study II”), Theralase® plans to commence a new human clinical study and is currently researching and developing the next cancer indications using Rutherrin®, a proprietary formulation of the lead PDC TLD-1433, combined with transferrin.